EPISODE · Aug 25, 2026 · 8 MIN
EXPLAINER: Human Age Reversal Has Begun
They just injected youth genes into a human eye. On June 9, 2026, a patient with glaucoma became the first human ever dosed with ER-100 — an epigenetic reprogramming gene therapy designed not just to slow aging, but to reverse it. In this solo explainer, Dr. Robert Lufkin breaks down the science of partial cellular reprogramming, the Harvard study that restored vision in old mice, the built-in genetic safety switch, and what this first-in-human trial really means — and doesn't mean — for the future of longevity.Chapters00:00 — Introduction: Youth Genes Injected Into a Human Eye00:41 — Glaucoma: Blindness That Only Moves in One Direction01:42 — The Harvard Mice That Got Their Vision Back02:05 — Yamanaka Factors and the OSK Gene Cocktail03:08 — June 9, 2026: First Human Dosed With ER-10003:54 — The Doxycycline Safety Switch Built Into the Genes04:35 — Aging as Lost Information: Hardware vs Software05:27 — Why Scientists Chose the Eye First06:05 — The Honest Caveat: Phase 1 Means Safety, Not Efficacy07:13 — The Takeaway: What Already Works for LongevityStudies & sources mentionedLu et al. 2020, Nature — OSK reprogramming restored vision in old mice: https://pubmed.ncbi.nlm.nih.gov/33268865/Tham et al. 2014, Ophthalmology — global glaucoma prevalence: https://pubmed.ncbi.nlm.nih.gov/24974815/Life Biosciences — first patient dosed in Phase 1 trial of ER-100: https://www.globenewswire.com/news-release/2026/06/09/3308634/0/en/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies.htmlTrial registration (NCT07290244): https://clinicaltrials.gov/study/NCT07290244⚠️ Honest caveat: this is a Phase 1, open-label safety trial in roughly 18 adults. The primary endpoint is safety and tolerability — not vision restoration. Nothing here is medical advice; this content is for educational purposes only.📕 Book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/📰 Weekly newsletter: https://robertlufkinmd.substack.com🌐 Website: https://robertlufkinmd.com⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every other Tuesday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/
Embed this episode
What this episode covers
They just injected youth genes into a human eye. On June 9, 2026, a patient with glaucoma became the first human ever dosed with ER-100 — an epigenetic reprogramming gene therapy designed not just to slow aging, but to reverse it. In this solo explainer, Dr. Robert Lufkin breaks down the science of partial cellular reprogramming, the Harvard study that restored vision in old mice, the built-in genetic safety switch, and what this first-in-human trial really means — and doesn't mean — for the ...
Ready to play
EXPLAINER: Human Age Reversal Has Begun
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.